BioVentrix, a developer of minimally invasive therapies for the treatment of heart failure, has elected two new members to its board of directors. George J. Fazio and Steven J. Healy were elected at the company’s recent annual meeting held in New York City.

Fazio has been in the medical device industry for twenty-five years. In 2010 he joined DC Devices, a medtech company that develops an interventional treatment for diastolic heart failure. He currently serves as president and CEO of the company. Prior to this appointment, he was with medical device company St. Jude Medical from 1992 to 2009. He joined the company as a sales representative, and rose through the ranks in the global cardiac business eventually becoming president of the U.S. division, Cardiovascular division, Cardiac Surgery division, president of Europe, Middle East and Africa business, and general manager of the Canadian operations. Fazio began his career as a sales and marketing professional for Davis and Geck’s surgical business. Fazio holds a Bachelor of Science degree from the State University of New York at Albany and an MBA from the Fordham University Graduate School of Business.

Healy currently is president of Zimmer Spine. Prior to Zimmer, he served as chairman, CEO, and a founding board member of Lumen Biomedical, an interventional cardiology company. From 2002 to 2009, he served as CEO of Disc Dynamics, an orthopedic medical technology company. Prior to this, he was president of the Cardiac Surgery Division at St. Jude Medical, where he held a variety of senior management positions prior to being promoted to president. Healy joined St. Jude Medical shortly after Fazio in 1983.

BioVentrix’s Chairman of the Board Michael Taglich expressed confidence that Fazio and Healy would “help to make this company the success it should be." He mentioned in a prepared statement that the two men had reviewed the company’s “promising clinical data and business plan.”

The San Ramon, Calif.-based company focuses exclusively on devices in the cardiac space, for which Fazio and Healy are well prepared. In particular, BioVentrix develops devices and technology to aid left ventricular volume and radius reduction for patients with advanced heart failure.

Kenneth Miller, company president and CEO, added:

"I am confident that the vast, collective experience of BioVentrix's board of directors will help to build upon our accomplishments and further enhance opportunities to drive value for our innovative, less invasive approach to treating heart failure."

News from our sister sites